RxDoctor Payments Data

David Kim, MD

Cardiovascular Disease · Columbia, MDNPI 1801803101

Payments from drug & device makers

$8,161in general payments, 2019–2025

Across 76 payments — averaging $107.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dynavax Technologies Corporation$5K
  • Abbott$973
  • Novartis$478
  • Medtronic$305
  • Boston Scientific$161
  • Biotronik Inc.$127
  • plus $716 from 11 others

What the payments were for

  • Consulting fees$5,40066%
  • Food & beverage$2,76134%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,161 in reported general payments places this provider in the 75th percentile of 507 cardiovascular disease providers in Maryland.

See all cardiovascular disease providers in Maryland

Medicare billing

Part B allowed, 2024
$273,798
Medicare patients
1,690
Services billed
4,287

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban350$419,995
XareltoRivaroxaban159$199,547
JardianceEmpagliflozin41$63,530
EntrestoSacubitril/Valsartan30$48,726
FarxigaDapagliflozin Propanediol20$26,063
Droxidopa19$14,535
Metoprolol Succinate366$7,362
Atorvastatin Calcium282$5,178
Valsartan96$3,664
Diltiazem 24hr Er (Cd)Diltiazem Hcl59$2,280
Nebivolol Hcl27$2,267
Chlorthalidone108$2,250
Flecainide Acetate29$2,004
Candesartan Cilexetil16$1,932
Losartan Potassium143$1,868

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$102$419,995350 claims
Johnson & JohnsonXarelto$45$199,547159 claims
NovartisEntresto$478$48,72630 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 507 cardiovascular disease providers in Maryland.

Other cardiovascular disease in Columbia

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →